CASQ2 and sudden infant death syndrome: The risk of SCD as the first clinical expression of the disease at a young age (even in infancy, associated with SIDS) justifies genetic screening starting from birth in a family with a known CPVT mutation to allow prompt initiation of prophylactic beta-blockers, with the remark that CASQ2-CPVT may be more severe and more resistant to beta-blockers.